(Arg)9 acetate (Synonyms: Nona-L-arginine acetate; Peptide R9 acetate) |
| رقم الكتالوجGC66389 |
(Arg) 9 (Nona-L-arginine) أسيتات هو ببتيد يخترق الخلايا (CPP) يتكون من 9 بقايا أرجينين. (Arg) 9 أسيتات لها خاصية اعصاب ، وتعرض نشاط اعصاب مع IC50 0.78 μ ؛ M في نموذج حمض الجلوتاميك.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 0.78 μM (neuroprotection)[1]
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].
(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].
| Animal Model: | Male Sprague-Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2] |
| Dosage: | 1 μM/kg (600 μL) |
| Administration: | Intravenous injection; once, over 5 minutes |
| Result: | Reduced significantiy 20% in infarct volume. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *